



From Publication to Pragmatic Trial: Barriers and Facilitators to Deploying Healthcare AI

Colin Walsh, MD, MA, FACMI, FAMIA, FIAHSI

Associate Professor of Biomedical Informatics, Medicine & Psychiatry

Vanderbilt University Medical Center

September 26, 2025

Goals and Objectives

- ▶ To highlight barriers and facilitators to translating published risk models into live clinical systems to support randomized clinical trials
- ▶ To present evidence that predictive decision support affects clinical decision-making
- ▶ To disseminate lessons learned to catalyze similar efforts elsewhere

TRIAL 1:
RISK MODEL-DRIVEN DECISION SUPPORT
TO GUIDE SUICIDE PREVENTION

Figure. Illustration of an Artificial Intelligence (AI) Development Pipeline

1 Anticipation of clinical outcomes the AI tool will address

- Engage clinicians, patients, and operational leaders
- Define characteristics of affected patients and clinical settings
- Define how and to whom the algorithm's results will be provided

2 Research and development of the AI tool

- Obtain data for algorithm development
- Develop algorithms using collected data
- Confirm early validation of algorithm

3 Replication

- Identify similar data sources
- Identify similar patients
- Replication by computer simulation

4 Design, testing, and deployment of the AI tool

- Design the platform for use
- Test usability and feasibility for operational deployment
- Create the operational platform

5 Improvement of determined outcomes

- Implement the operational platform
- Test effectiveness in a pragmatic trial
- Implement the AI tool and algorithm-guided practice systemwide



VIEWPOINT


Action-Informed Artificial Intelligence— Matching the Algorithm to the Problem

Christopher J. Lindsell, PhD¹; William W. Stead, MD^{2,3}; Kevin B. Johnson, MD, MS^{2,4}



NCBI Literature Collection

Design and Deploy – Start in “Silent Mode”



Original Investigation | Health Informatics

Prospective Validation of an Electronic Health Record-Based, Real-Time Suicide Risk Model

Colin G. Walsh, MD, MA; Kevin B. Johnson, MD, MS; Michael Ripperger; Sarah Sperry, PhD; Joyce Harris; Nathaniel Clark, MD; Elliot Fielstein, PhD; Laurie Novak, PhD, MHSA; Katelyn Robinson; William W. Stead, MD



Original Investigation | Psychiatry


Integration of Face-to-Face Screening With Real-time Machine Learning to Predict Risk of Suicide Among Adults

Drew Wilimitis, BS; Robert W. Turer, MD, MS; Michael Ripperger, BE; Allison B. McCoy, PhD; Sarah H. Sperry, PhD; Elliot M. Fielstein, PhD; Troy Kurz, MD; Colin G. Walsh, MD, MA


Set Benchmarks for Go/No-Go Decisions

Care Site	AUROC (95% CI)
Suicide attempt	
Medical center wide	0.797 (0.796 to 0.798)
Emergency department	0.7 (0.699 to 0.7)
Adult hospital	0.842 (0.841 to 0.842)
Behavioral health	0.544 (0.539 to 0.548)

Integrate into existing workflow



Integrate into existing workflow



The Clinical Decision Support

The screenshot displays a clinical decision support system interface. On the left, a patient profile for Kam C. Neurology is shown, including demographic information and a list of medications. A purple box highlights a yellow alert icon labeled "Elevated Suicide Risk". The main area shows a "Plan" tab with a "BestPractice Advisory - Neurology, Kam C" alert. The alert text states: "Vanderbilt AI has reviewed your patient's chart and noted risk factors placing them at an elevated risk of suicide. We did not find a recent suicide risk screening in their patient record." Below this, a disclaimer mentions a randomized controlled trial. A link "Click Here to Document Using CSSRS (Takes 10 sec - 3 min)" is provided. An "Acknowledge Reason" section has three buttons: "Will screen with alternative method", "Disagree with this alert", and "Already screened today". At the bottom of the alert are "Accept" and "Dismiss" buttons. The background interface includes various tabs like "Medication Management", "SmartSets", and "Outpatient Medications".

Figure 2. Participant Flow Diagram




Figure 2. Participant Flow Diagram




Figure 3. Flowchart of Trial Outcomes by Arm






Figure 2. Participant Flow Diagram



JAMA Network Open. 2025;8(1):e2452371. doi:10.1001


FINDINGS

Interruptive CDS led to significantly higher numbers of decisions to screen for suicide risk in person compared with noninterruptive CDS




Odds ratio of in-person suicide risk assessment with interruptive CDS vs noninterruptive CDS,
17.70 (95% CI, 6.42-48.79; $P < .001$)


rm





TRIAL 2:
PREVENTING HOSPITAL ACQUIRED
VENOUS THROMBOEMBOLISM AT SCALE



50%
of blood clots are
healthcare-associated



StopTheClot.org




VTE-AI Risk Score

A real-time prognostic model for venous thromboembolic events among hospitalized adults


Benjamin F. Tillman¹ | Henry J. Domenico² | Ryan P. Moore² | Daniel W. Byrne² | Colleen T. Morton¹ | Amanda S. Mixon^{3,4,5} | Benjamin French² 

Variable	Coefficient
Intercept	-11.2511
Type of admission	
Elective (reference)	0
Emergency department	-0.1504
Trauma	0.9220
Inter-hospital transfer	0.2587
Unknown	0.4447
Heart rate, bpm (if unknown, use 85 bpm)	0.0066
Acute kidney injury comorbidity	0.3456
Candidal stomatitis comorbidity	0.4224
Cardiac arrhythmia comorbidity	1.0437
Cerebrovascular disease comorbidity	0.3128
Coagulopathy comorbidity	0.5130
Fluid or electrolyte disorder comorbidity	0.9052
Hypoxemia comorbidity	0.6224
Other anemia comorbidity	0.3740
Other psychiatric disorders comorbidity	0.3457
Paralysis comorbidity	0.2424
Peptic ulcer disease comorbidity	0.4756
Pleural disease comorbidity	0.5110
Pneumonia comorbidity	0.6928
Respiratory symptoms comorbidity	0.2332
Weight loss comorbidity	0.6310
Central line placed	1.1426
Sodium, mEq/L (if unknown, use 138 mEq/L)	0.0182
Chloride, mEq/L (if unknown, use 105 mEq/L)	0.0110
Blood urea nitrogen, mg/dL (if unknown, use 16 mg/dL)	-0.0089
C-reactive protein, mg/dL (if unknown, use 39.0 mg/dL)	0.0033

Silent validation -> Feature reengineering to prevent model failure



An every day clinical decision belies complexity...



An every day clinical decision belies complexity...

So navigate it by building bridges

having meetings

lots of meetings

designing within a dynamic system

and double-checking your work

- SafeCourse RCT added to literature on Directive CDS driving behavior more effectively
- VTE-AI RCT launches September 2025 (VUMC IRB #241978, ClinicalTrials.gov Registered NCT06939803)
- Both required in silico validation, go/no-go decisions based on clinical benchmarks, and diligent bridge-building to those who tackle hard clinical problems every day

Funding Sources

NIMHR01 LM010685, MH121455, MH120122, MH116269

Evelyn Stead Center for Innovation Fund

AIM HI

